Publications by authors named "Raffit Hassan"

100Publications

Response to Letter to Editor by Cornelissen et al.

J Thorac Oncol 2020 Oct;15(10):e169-e170

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.07.003DOI Listing
October 2020

UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

J Thorac Oncol 2020 Sep 11. Epub 2020 Sep 11.

Thoracic Epigenetics Section, Thoracic Surgery Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.08.024DOI Listing
September 2020

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.

Sci Transl Med 2020 Jul;12(550)

Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaz7252DOI Listing
July 2020

Response to Letter to the Editor by Yang et al.

J Thorac Oncol 2020 06;15(6):e91

Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.03.033DOI Listing
June 2020

FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.

J Nucl Med 2020 Apr 13. Epub 2020 Apr 13.

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.238733DOI Listing
April 2020

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

Front Oncol 2020 12;10:343. Epub 2020 Mar 12.

Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080957PMC
March 2020

Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases.

J Thorac Oncol 2020 02;15(2):e25-e27

Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.08.2504DOI Listing
February 2020

Orbital metastases from malignant mesothelioma.

Lancet Oncol 2020 02;21(2):e117

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30822-8DOI Listing
February 2020

Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.

J Thorac Oncol 2020 03 26;15(3):457-461. Epub 2019 Nov 26.

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.11.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044061PMC
March 2020

Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.

Am J Ind Med 2020 02 19;63(2):105-114. Epub 2019 Nov 19.

Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajim.23062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427840PMC
February 2020

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

J Patient Rep Outcomes 2019 Jun 17;3(1):34. Epub 2019 Jun 17.

Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41687-019-0122-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579804PMC
June 2019

Targeting mesothelin in ovarian cancer.

Oncotarget 2018 Nov 16;9(90):36050-36051. Epub 2018 Nov 16.

Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281414PMC
November 2018

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

J Thorac Oncol 2018 09;13(9):1269-1283

Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643278PMC
September 2018

Reply to D. de Fonseka et al.

J Clin Oncol 2018 09 14;36(26):2746-2747. Epub 2018 Jun 14.

Hedy L. Kindler, The University of Chicago, Chicago, IL; Valerie Rusch, Memorial Sloan Kettering Cancer Center, New York NY; Raphael Bueno, Harvard Medical School, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria VA; Harvey Pass and Daniel Sterman, New York University Langone Medical Center, New York, NY; and Raffit Hassan, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7333DOI Listing
September 2018

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.

J Oncol Pract 2018 04 8;14(4):256-264. Epub 2018 Mar 8.

The University of Chicago, Chicago, IL; American Society of Clinical Oncology, Alexandria VA; and National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.17.00012DOI Listing
April 2018

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 05 18;36(13):1343-1373. Epub 2018 Jan 18.

Hedy L. Kindler and Samuel G. Armato III, The University of Chicago, Chicago, IL; Nofisat Ismaila, American Society of Clinical Oncology; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Alexandria, VA; Raphael Bueno, Harvard Medical School, Boston, MA; Thierry Jahan, University of California San Francisco, San Francisco, CA; Clyde Michael Jones, Baptist Cancer Center Physicians Foundation, Memphis, TN; Markku Miettinen, Anish Thomas and Raffit Hassan, Center for Cancer Research, National Cancer Institute, Bethesda, MD; Harvey Pass and Daniel Sterman, New York University Langone Medical Center; and Andreas Rimner and Valerie Rusch, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.6394
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.6394DOI Listing
May 2018

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 06 18;36(16):1594-1602. Epub 2017 Dec 18.

Anish Thomas, Christophe E. Redon, Linda Sciuto, Emerson Padiernos, Min-Jung Lee, Akira Yuno, Sunmin Lee, Arun Rajan, Udayan Guha, Haobin Chen, Raffit Hassan, Christine C. Alewine, Eva Szabo, Seth M. Steinberg, James H. Doroshow, Mirit I. Aladjem, Jane B. Trepel, and Yves Pommier, National Cancer Institute, Bethesda; Jiuping Ji, Yiping Zhang, Lan Tran, William Yutzy, and Robert J. Kinders, Frederick National Laboratory for Cancer Research, Frederick, MD; and Susan E. Bates, Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978471PMC
June 2018

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway.

Oncotarget 2017 Oct 14;8(50):87307-87316. Epub 2017 Aug 14.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675634PMC
October 2017

CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?

Lancet Oncol 2017 09 17;18(9):1150-1151. Epub 2017 Jul 17.

Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30511-9DOI Listing
September 2017

Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health.

Clin Genitourin Cancer 2017 10 22;15(5):e871-e875. Epub 2017 May 22.

Urologic Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.04.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623092PMC
October 2017

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

J Clin Oncol 2016 12 31;34(34):4171-4179. Epub 2016 Oct 31.

Raffit Hassan, Anish Thomas, Christine Alewine, and Ira Pastan, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda; and Dung T. Le and Elizabeth M. Jaffee, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.68.3672
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.68.3672DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477819PMC
December 2016

Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.

Lung Cancer 2016 11 28;101:104-110. Epub 2016 Sep 28.

Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.09.015DOI Listing
November 2016

Antibody-drug conjugates for cancer therapy.

Lancet Oncol 2016 06;17(6):e254-e262

Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045163003
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(16)30030-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601617PMC
June 2016

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.

Oncotarget 2016 May;7(21):29916-26

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/9171
Publisher Site
http://dx.doi.org/10.18632/oncotarget.9171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058652PMC
May 2016

Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.

Appl Immunohistochem Mol Morphol 2016 Apr;24(4):246-52

*Department of Pathology ‡The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore †Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821730PMC
April 2016

New Life for Immunotoxin Cancer Therapy.

Clin Cancer Res 2016 Mar 13;22(5):1055-8. Epub 2015 Oct 13.

Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/10/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-1623DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775389PMC
March 2016

New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.

Sci Rep 2015 May 21;5:9928. Epub 2015 May 21.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Bethesda, MD 20892, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep09928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440525PMC
May 2015

Advances in anticancer immunotoxin therapy.

Oncologist 2015 Feb 5;20(2):176-85. Epub 2015 Jan 5.

Laboratory of Molecular Biology and Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0358DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319635PMC
February 2015

Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.

PLoS One 2014 13;9(8):e104388. Epub 2014 Aug 13.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0104388PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132110PMC
April 2015

Discovery of mesothelin and exploiting it as a target for immunotherapy.

Cancer Res 2014 Jun 13;74(11):2907-12. Epub 2014 May 13.

Authors' Affiliation: Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062095PMC
June 2014

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Proc Natl Acad Sci U S A 2014 Jun 5;111(23):8571-6. Epub 2014 May 5.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1405153111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060717PMC
June 2014

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Gastroenterology 2014 Jun 6;146(7):1784-94.e6. Epub 2014 Mar 6.

The Sidney Kimmel Comprehensive Cancer Center, the Skip Viragh Center for Clinical Pancreatic Cancer Research, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2014.02.055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035450PMC
June 2014

Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.

Sci Transl Med 2013 Oct;5(208):208ra147

Laboratory of Molecular Biology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3006941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369691PMC
October 2013

Clinical and pathological features are still the best determinants of prognosis in mesothelioma.

Oncology (Williston Park) 2012 Dec;26(12):1176, 1178, 1180

Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352303PMC
December 2012

New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Am J Pathol 2013 Apr 8;182(4):1065-77. Epub 2013 Feb 8.

Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont 05405-0068, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2012.12.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657618PMC
April 2013

Farletuzumab in lung cancer.

Lung Cancer 2013 Apr 26;80(1):15-8. Epub 2013 Jan 26.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.12.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595339PMC
April 2013

Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Anticancer Res 2012 Dec;32(12):5151-8

Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309901PMC
December 2012

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Mol Cancer Ther 2013 Jan 6;12(1):48-57. Epub 2012 Nov 6.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546136PMC
January 2013

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.

Proc Natl Acad Sci U S A 2012 Jul 2;109(29):11782-7. Epub 2012 Jul 2.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1209292109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406843PMC
July 2012

Immunotherapies for non-small-cell lung cancer and mesothelioma.

Lancet Oncol 2012 Jul 28;13(7):e301-10. Epub 2012 Jun 28.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(12)70126-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317076PMC
July 2012

Mesothelin-targeted agents in clinical trials and in preclinical development.

Mol Cancer Ther 2012 Mar 17;11(3):517-25. Epub 2012 Feb 17.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297681PMC
March 2012

Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.

Int J Cancer 2012 Nov 24;131(9):2143-52. Epub 2012 Apr 24.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371100PMC
November 2012

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Clin Chem Lab Med 2012 Apr;50(4):721-5

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/CCLM.2011.816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309905PMC
April 2012

Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.

Cancer Res 2011 Sep 20;71(17):5915-22. Epub 2011 Jul 20.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-0466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165076PMC
September 2011

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

Nucl Med Biol 2011 Nov 7;38(8):1119-27. Epub 2011 Jul 7.

Radiopharmaceutical Laboratory, Division of Nuclear Medicine, Department of Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2011.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426867PMC
November 2011

Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

Lung Cancer 2011 Sep 28;73(3):256-63. Epub 2011 May 28.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.04.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148297PMC
September 2011

Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.

Clin Cancer Res 2011 Jun 26;17(11):3697-705. Epub 2011 Apr 26.

Center for Cancer Research, National Institutes of Health, Experimental Transplantation and Immunology Branch, and Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107891PMC
June 2011

In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.

J Cancer 2011 Mar 1;2:123-31. Epub 2011 Mar 1.

1. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072618PMC
http://dx.doi.org/10.7150/jca.2.123DOI Listing
March 2011

The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.

PLoS One 2011 Jan 31;6(1):e14640. Epub 2011 Jan 31.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0014640PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031536PMC
January 2011

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Clin Cancer Res 2010 Dec 29;16(24):6132-8. Epub 2010 Oct 29.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057907PMC
December 2010

A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.

Cancer Res 2010 Feb 26;70(3):1082-9. Epub 2010 Jan 26.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-2405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818704PMC
February 2010

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Lung Cancer 2010 Jun 9;68(3):455-9. Epub 2009 Sep 9.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002090042
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2009.07.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864325PMC
June 2010

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Clin Cancer Res 2009 Aug 11;15(16):5274-9. Epub 2009 Aug 11.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754261PMC
August 2009

A binding domain on mesothelin for CA125/MUC16.

J Biol Chem 2009 Feb 15;284(6):3739-49. Epub 2008 Dec 15.

Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/content/284/6/3739.full.pdf
Web Search
http://www.jbc.org/cgi/doi/10.1074/jbc.M806776200
Publisher Site
http://dx.doi.org/10.1074/jbc.M806776200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635045PMC
February 2009

Malignant mesothelioma of the inguinal canal with an unusually long survival.

Am J Clin Oncol 2008 Jun;31(3):306-7

National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000204404.36736.69DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217321PMC
June 2008

Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.

Clin Cancer Res 2007 Dec;13(23):7166-71

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, and the Clinical Center, NIH, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1592DOI Listing
December 2007

Mesothelin targeted cancer immunotherapy.

Eur J Cancer 2008 Jan 22;44(1):46-53. Epub 2007 Oct 22.

Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4264, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2007.08.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2265108PMC
January 2008

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.

Proc Natl Acad Sci U S A 2007 Oct 16;104(43):17099-104. Epub 2007 Oct 16.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.0708101104
Publisher Site
http://dx.doi.org/10.1073/pnas.0708101104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040446PMC
October 2007

Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.

Eur J Haematol 2007 Oct 4;79(4):281-6. Epub 2007 Sep 4.

University Children's Hospital Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2007.00928.xDOI Listing
October 2007

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Clin Cancer Res 2007 Sep;13(17):5144-9

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892-4264, USA. .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0869DOI Listing
September 2007

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Bioconjug Chem 2007 May-Jun;18(3):773-84. Epub 2007 Mar 9.

Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New Jersey 08854, and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc060314xDOI Listing
August 2007

Mesothelin expression in human lung cancer.

Clin Cancer Res 2007 Mar;13(5):1571-5

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2161DOI Listing
March 2007

Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.

J Immunol 2006 Dec;177(12):8822-34

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.177.12.8822DOI Listing
December 2006

Immunotoxin treatment of cancer.

Annu Rev Med 2007 ;58:221-37

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev.med.58.070605.115320DOI Listing
April 2007